Premium
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5
Author(s) -
CARLOSTELLA C.,
Linhares Y.,
Gandhi M. D.,
Chung M.,
Adamis H.,
Ungar D.,
Hamadani M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.163_2880
Subject(s) - medicine , rituximab , diffuse large b cell lymphoma , clinical endpoint , oncology , neutropenia , refractory (planetary science) , phases of clinical research , oxaliplatin , gemcitabine , lymphoma , gastroenterology , surgery , randomized controlled trial , clinical trial , toxicity , chemotherapy , cancer , astrobiology , physics , colorectal cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom